Last reviewed 2026-04-23 · How we verify

PROVARIX

PROVARIX is a recombinant varicella-zoster virus (VZV) vaccine designed to prevent herpes zoster (shingles) and post-herpetic neuralgia in immunocompetent and immunocompromised populations.

PROVARIX is a recombinant varicella-zoster virus (VZV) vaccine designed to prevent herpes zoster (shingles) and post-herpetic neuralgia in immunocompetent and immunocompromised populations. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of post-herpetic neuralgia in adults aged 50 years and older.

At a glance

Mechanism of action

The vaccine contains recombinant VZV glycoprotein E (gE) combined with an AS01B adjuvant system to enhance immune response. It stimulates both cellular and humoral immunity against VZV, providing protection against reactivation of latent virus that causes shingles and its complications.

Approved indications

• Prevention of herpes zoster (shingles) in adults aged 50 years and older
• Prevention of post-herpetic neuralgia in adults aged 50 years and older

Common side effects

• Injection site pain
• Injection site erythema
• Myalgia
• Fatigue
• Headache

Key clinical trials

• Second Dose of Varicella Vaccine in Healthy Children (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PROVARIX CI brief — competitive landscape report
• PROVARIX updates RSS · CI watch RSS
• Sinovac (Dalian) Vaccine Technology Co., Ltd. portfolio CI